Published Technical Disclosure Archive

Synergistic CAR-T Cell Production and Therapy System

Publication ID: 24-11857572_0008_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic CAR-T Cell Production and Therapy System,” Published Technical Disclosure No. 24-11857572_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857572_0008_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,572.

Summary of the Inventive Concept

A comprehensive system integrating CAR-T cell production, AI-driven quality control, IoT-enabled monitoring, and blockchain-based supply chain management to enhance personalized cancer treatment

Background and Problem Solved

The original patent disclosed a method for preparing CAR-T cells with TCM as the main active component, but it had limitations in terms of scalability, quality control, and patient monitoring. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful system

Detailed Description of the Inventive Concept

The system comprises a microfluidic device for sorting and isolating TCM cells, a machine learning-based algorithm for optimizing CAR design, and a blockchain-based ledger for tracking CAR-T cell production and distribution. Additionally, the system integrates IoT-enabled biosensors for real-time monitoring of TCM cell activity, AI-driven analytics for predicting and preventing TCM cell exhaustion, and a decentralized blockchain-based supply chain management system for tracking and verifying CAR-T cell products. The system can be further customized using patient genomic data to design personalized CAR-T cell therapy

Novelty and Inventive Step

The new inventive concept introduces a synergistic combination of AI, IoT, blockchain, and microfluidic technologies to enhance CAR-T cell production and therapy, which is not obvious from the original patent. The integration of these distinct technologies provides a new and non-obvious solution for personalized cancer treatment

Alternative Embodiments and Variations

Alternative embodiments may include using different types of biosensors, varying the machine learning algorithm for CAR design optimization, or implementing different blockchain protocols for supply chain management. Variations may also include integrating additional technologies, such as new materials for CAR-T cell expansion or augmented reality for patient monitoring

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the cancer treatment market, particularly in the areas of personalized medicine and immunotherapy. The system's ability to enhance CAR-T cell production and therapy can lead to improved treatment outcomes and reduced costs. Target industries include biotech, pharmaceutical, and healthcare

Field of Art

Immunotherapy, cell engineering, and biotechnology with a focus on CAR-T cell production and personalized cancer treatment technologies

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer or immunologist with advanced degrees, expertise in cell manipulation techniques, machine learning applications in biotechnology, and familiarity with emerging medical technologies

Obviousness Rationale

The PTD represents an obvious extension of the source patent's CAR-T cell technology by applying standard engineering techniques of integrating digital technologies with biological systems. A PHOSITA would recognize that combining machine learning, IoT, and blockchain with existing CAR-T cell production methods represents a predictable application of known technologies to improve existing cell therapy approaches.

Obvious Combinations & Variations

Source Patent Element
CAR-T cell method using central memory T cells with artificial antigenic epitopes
PTD Variation
Microfluidic device for sorting and isolating TCM cells with AI-driven CAR design optimization
Obviousness Reasoning
A PHOSITA would find it obvious to apply machine learning and precision sorting techniques to improve cell isolation and CAR design, as these are standard techniques in cell engineering with predictable improvements in cell therapy development
Source Patent Element
T cell subset with specific surface markers (CD45RO+/CD197+)
PTD Variation
IoT-enabled biosensors for real-time monitoring of TCM cell activity
Obviousness Reasoning
Integrating monitoring technologies with cell therapy is a known approach, and a PHOSITA would recognize the predictable benefit of real-time cellular activity tracking using standard IoT sensor technologies
Source Patent Element
CAR-T cell production method for cancer treatment
PTD Variation
Blockchain-based supply chain management and patient data tracking system
Obviousness Reasoning
Applying blockchain to medical technology tracking is a known technique, and a PHOSITA would find it an obvious solution for improving traceability and data management in personalized cell therapies
Source Patent Element
Method for increasing yield of central memory T cells
PTD Variation
AI-driven analytics for predicting and preventing TCM cell exhaustion
Obviousness Reasoning
Predictive analytics applied to cellular therapies represent a standard engineering approach, and a PHOSITA would recognize this as an obvious extension of existing cell production optimization techniques
Source Patent Element
CAR-T cell method with artificial antigenic epitopes
PTD Variation
Personalized CAR design using patient genomic data
Obviousness Reasoning
Customizing medical treatments using patient-specific genetic information is a known approach, and a PHOSITA would find it an obvious method to improve CAR-T cell therapy effectiveness
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed in this publication would be obvious to a person having ordinary skill in the art at the time of invention, as they represent predictable combinations of known technologies with the foundational CAR-T cell method disclosed in US Patent 11857572, utilizing standard engineering techniques to enhance cell therapy production and personalization.

Original Patent Information

Patent NumberUS 11,857,572
TitleMethod for preparing CAR-T cell with TCM as main active component and use thereof
Assignee(s)Xuanwu Hospital Capital Medical University